Clinical Trial Update: Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial comparing maraviroc added to optimized background therapy versus optimized background therapy alone in antiretroviral-experienced, non-CCR5-tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Maraviroc (maraviroc)

Snippet

Sponsor: ViiV Healthcare | Conditions: HIV Infections | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2010-10-21